Life Technologies Launches CE-IVD Marked QuantStudio™ Dx Real-Time PCR Instrument in Europe

Informations

• Publié par: life-technologies-pr
• Nombre de lectures: 14
• Langue: English

Extrait

Life Technologies Launches CE-IVD Marked QuantStudio™ Dx Real-Time PCR Instrument in Europe

PR Newswire CARLSBAD, California, November 19, 2012

CARLSBAD, California,November 19, 2012/PRNewswire/ --

Flagship qPCR instrument offers reliability, accuracy, ease of use and flexibility for IVD and lab-developed diagnostic tests

Life Technologies Corporation(NASDAQ:LIFE) today announced the launch of its Applied Biosystems QuantStudio™ Dx Real-Time PCR Instrument designed to meet the specific needs of clinical diagnostic laboratories. The instrument is CE-IVD marked for use in Europe and represents a significant extension of Life Technologies' product offerings in the diagnostics arena.

Life Technologies Corporation "Molecular diagnostic tests based on real-time PCR have become indispensable to the clinical lab," saidRonnie Andrews, president of Medical Sciences at Life Technologies. "Molecular testing is the fastest-growing segment of the diagnostics market, and the QuantStudio™ Dx instrument has unique features that will allow us to capture that market growth."

The global IVD (in vitro diagnostic) market is approximately$52 billionand is expected to reach$70 billionby 2015. [1] The current European IVD market is approximately$14 billionand expected to reach$17 billionby 2015.

The QuantStudio™ Dx Real-Time PCR Instrument can perform numerous diagnostic functions, including pathogen detection, gene expression analysis, SNP genotyping, copy number analysis, mutation detection, micro-R NA and other non-coding RNA analysis, and high-resolution melt analysis.

The instrument's touchscreen, reagent and sample tracking, and LIMS (Laboratory Information Management Systems) interface are specifically designed for ease of use. Flexibility is enabled through easily interchangeable thermal cycling blocks that accommodate 96- or 384-well plates and a proprietary qPCR microfluidics card, which can perform 48 tests on eight samples simultaneously without the need for liquid-handling robots. The card can also be used to design and implement custom tests. Life Technologies is currently developing diagnostic tests utilizing this format.

Two software options are available on the instrument. The QuantStudio™ Dx Software runs IVD (in vitrodiagnostic) tests in a secure mode with pre-set run and analysis parameters, while the QuantStudio™ Test Development Software enables development of custom tests and supports clinical research projects.

"We recognize that clinical laboratories have multiple needs," said Andrews. "Accuracy and reliability are paramount when running diagnostic tests for physician reporting. In addition medical research labs need instrumentation that supports experimental work. The QuantStudio™ Dx instrument addresses both these needs."

The instrument is being released with CE-marked Quidel® Molecular Assay forC. difficilefor detection of hospital- acquired infections, which Life Technologies distributes. Additional Quidel Molecular infectious disease applications are currently under development and will be available in 2013, including an influenza A + B Assay, a human metapneuomvirus (hMPV) + respiratory syncytial virus (RSV) Assay, and a herpes simplex virus 1 and 2, and varicella zoster virus (chicken pox and shingles) Assay.

Life Technologies plans to submit the QuantStudio™ Dx Real-Time PCR Instrument for 510(k) clearance to the United States Federal Food and Drug Administration (FDA) inDecember 2012.

The QuantStudio™ Dx Real-Time PCR Instrument is among a growing line of Life Technologies platforms for diagnostic use. The Applied Biosystems 3500 Dx Genetic Analyzer, a Sanger sequencing instrument, is currently CE-IVD marked. The company also offers the AcroMetrix® line of quality controls for molecular diagnostic assays.

"The Life Technologies Applied Biosystems brand has a 30-year heritage of leadership in the PCR market," said Andrews. "We also have a broad partnership base in the diagnostic and pharmaceutical space that will support content development across our Sanger and next generation sequencing instruments - platforms that we expect will play an increasingly important role in the clinic. In short, Life Technologies has the capability and the commitment to fully equip the diagnostic lab of the future."

For more information, please visithttp://www.lifetechnologies.com/quantstudiodx.html.

[1] DeciBio LLC, Molecular Diagnostics: Market Size, Segmentation, Growth and Opportunities,February 2012

About Life Technologies

Life Technologies Corporation(NASDAQ: LIFE) is a global biotechnology company w ith customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of$3.7 billionin 2011. Visit us at our website: http://www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies w ith the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.